Navigation Links
Orexigen Therapeutics to Present at Upcoming Investor Conferences
Date:2/7/2013

SAN DIEGO, Feb. 7, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:The 15th Annual BIO CEO & Investor Conference Date:

Tuesday, February 12, 2013Time:

2:00 p.m. Eastern TimeLocation:

The Waldorf Astoria, New York2013 Leerink Swann Global Healthcare Conference Date:

Wednesday, February 13, 2013Time:

11:30 a.m. Eastern Time Location:

The Waldorf Astoria, New YorkThe BIO CEO & Investor Conference presentation will be webcast live. To access the webcast, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

Orexigen Contact: McDavid Stilwell
VP, Corporate Communications and Business Development 
(858) 875-8629

Media Contact: Denise Powell
BrewLife
(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 ... the collapse of one or more vertebral bodies, ... Osteoporosis, a degenerative bone disease, is a leading ... disease, multiple myeloma, metastatic spinal tumors, and traumatic ... undergo vertebroplasty and kyphoplasty to rectify the condition. ...
(Date:9/2/2015)... Sept. 2, 2015 Advanced Wound Dressings ... Advanced dressings have steadily replaced traditional bandages ... variety of wound indications, such as trauma wounds, ... control, and physical protection become increasingly critical in ... in standard therapy. This report focuses on ...
(Date:9/2/2015)... 2015 Advanced Wound Dressings - 5EU ... dressings have steadily replaced traditional bandages and gauze ... wound indications, such as trauma wounds, burns, and ... physical protection become increasingly critical in wound healing, ... therapy. This report focuses on nine market ...
Breaking Medicine Technology:Global Balloon Kyphoplasty Market 2015-2019 2Advanced Wound Dressings - SA Analysis and Market Forecasts 2Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2
... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
... Phase 3 trial announced in December 2008; data from second ... trials of darapladib for cardiovascular disease and Syncria(R) for type ... $106 million of convertible debt repurchased for $50 million ... to $250 million; at least $150 million from delivery of ...
Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 9Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments 10
(Date:9/2/2015)... ... ... Chris Harrison of Harrison’s Footwear of Poulsbo announces the launch of his new ... have a lot of repeat customers, and many of them drive quite a distance ... them the convenience of ordering from home.” , Harrison’s Footwear has gained a reputation ...
(Date:9/2/2015)... DC (PRWEB) , ... September 02, 2015 , ... Telehealth ... American Well Corp., contracted to handle the telehealth services of more than 12 Blues ... Cross and Blue Shield Plans takes a look this growing trend, interviewing executives at ...
(Date:9/2/2015)... ... September 02, 2015 , ... ERT, ... collection, cloud analytics and workflow solutions today announced the September 2015 installments ... to participate in interactive programs in which ERT scientists and partner subject ...
(Date:9/2/2015)... ... September 02, 2015 , ... Density measurement is used in ... sample handling makes density measurements more efficient and error-free. The new METTLER TOLEDO ... workflow and the advantages compared to manual sample handling. , The Evolution of ...
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda ... in commemorating “Hunger Action Month” during the entire month of September. In ... will be dedicating its efforts this September to an awareness campaign educating legislators ...
Breaking Medicine News(10 mins):Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4
... Forest Laboratories, Inc.,(NYSE: FRX ), an ... its Fiscal 2008 Second Quarter financial results,before the ... 2007. Later that,day, at 10:00 AM EDT, Forest ... President and Chief Operating Officer and Frank Perier, ...
... The Care Net Board of,Directors has announced that ... Kurt Entsminger as interim President of Care Net.,The Board ... Entsminger, who,announced his resignation last month, served Care Net ... President since 2003., "The work of Care Net ...
... 8 QMed, Inc., (Nasdaq:,QMED) today announced that it ... an additional three years. Under the terms of the ... and coronary,heart disease. In addition, the Company receives a ... performance measures. Jane Murray, QMed president and CEO ...
... Oct. 8 The Integrated Healthcare,Association (IHA) ... Regional Medical Group (SRMG), affiliated with Sutter ... Pay for Performance (P4P),Stakeholders Meeting last week. ... performance overall on important,health care quality measures, ...
... finds little difference in chemotherapy treatment; some critics say ... News) -- A 2003 overhaul of Medicare that changed ... not alter cancer patients, perceptions of their quality of ... found that cancer patients are waiting the same amount ...
... that will ... LANSING, Mich., Oct. 8 In a bold move ... up to 500 new jobs for,Lansing and further revitalize the ... Insurance Company of America announced,today it will establish its new ...
Cached Medicine News:Health News:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings 2Health News:Care Net Announces New Leadership: Melinda Delahoyde to Follow Kurt Entsminger as President 2Health News:QMed, Inc. Extends Agreement & Receives $550,000 Performance Bonus 2Health News:Solano Regional Medical Group and Sutter Regional Medical Foundation Recognized by Integrated Healthcare Association (IHA) 2Health News:Medicare Changes Didn't Alter Cancer Care 2Health News:Medicare Changes Didn't Alter Cancer Care 3Health News:Medicare Changes Didn't Alter Cancer Care 4Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 2Health News:Accident Fund Will Make Board of Water & Light's Ottawa Street Station Power Plant in Lansing Its New National Headquarters 3
... ensures comfort and immobilization with ... frame and occipital component. Two-piece ... and easy application. Large trachea ... added comfort, removable, flannel-covered, open-cell ...
... Collars improves patient compliance, prevent skin ... to user's anatomy, wicks moisture, and ... to shoulders and upper throacic. Fits ... back airflow openings. Adjustable Occipital Support ...
... patient need and comfort in mind, ... of products effectively address a variety ... frame attachment provides optimal post-operative support, ... superior support for patient maintenance and ...
Effectively stabilize and relax your back with the LumboTrain back support....
Medicine Products: